AUTHOR=Gan Junqing , Meng Qingwei , Li Yanjing 

TITLE=Systematic Analysis of Expression Profiles and Prognostic Significance for FAM83 Family in Non-small-Cell Lung Cancer

JOURNAL=Frontiers in Molecular Biosciences

VOLUME=7

YEAR=2020

URL=https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2020.572406

DOI=10.3389/fmolb.2020.572406

ISSN=2296-889X

ABSTRACT=<sec><title>Background</title><p>Lung cancer remains a common malignancy and the leading cause of cancer-related deaths in the world. Although dramatic progress made in multimodal therapies, it still has a poor prognosis. The Family with sequence similarity 83 (<italic>FAM83</italic>) of poorly characterized proteins are defined by the presence of the conserved DUF1669 domain of unknown function at their N-termini, most of which significantly elevated levels of expression in multiple cancers. However, the expression and prognostic values of different <italic>FAM83</italic> family in lung cancer, especially in non-small-cell lung cancer (NSCLC), have not been clarified.</p></sec><sec><title>Methods</title><p>ONCOMINE, UALCAN, GEPIA, Kaplan–Meier Plotter, cBioPortal, and STRING databases were utilized in this study.</p></sec><sec><title>Results</title><p>The transcriptional levels of <italic>FAM83</italic>A/B/C/D/F/G/H were up-regulated in patients with NSCLC. A noticeable correlation was found between the over-expressions of <italic>FAM83A/B/D/F/H</italic> and clinical cancer stages in NSCLC patients. Besides, higher mRNA expressions of <italic>FAM83A/B/C/D/F/H</italic> were discovered to be expressively associated with overall survival (OS) in lung cancer patients, furthermore, <italic>FAM83A</italic>, <italic>FAM83C</italic>, and <italic>FAM83H</italic> in OS group achieved 0.9475/1, 0.971897/1, and 0.9454545/0.8974359 specificity/sensitivity in distinguishing short survivors from long survivors, respectively. Moreover, a high mutation rate of <italic>FAM83</italic> family (51%) was also observed in lung adenocarcinoma (LUAD) patients, and genetic alteration in the <italic>FAM83</italic> family was associated with shorter OS and disease-free survival (DFS) in LUAD patients.</p></sec><sec><title>Conclusion</title><p>Our results indicated that <italic>FAM83A/H</italic> might play important roles in NSCLC tumorigenesis and might be risk factor for the survival of NSCLC patients.</p></sec>